NKTR - Company ID 0000906709
The table below shows NEKTAR THERAPEUTICS's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $55.23M | $98.43M | $90.12M | $92.06M | $101.91M | $152.91M |
| Cost of revenue | $0.00 | $30.69M | $33.77M | $21.64M | $24.90M | $19.48M |
| Gross profit | - | - | - | - | - | - |
| R&D | $117.33M | $120.91M | $114.16M | $218.32M | $400.27M | $408.68M |
NEKTAR THERAPEUTICS reported annual revenue of $55.23M for fiscal year 2025. That is down 43.9% from $98.43M in fiscal 2024. Over the 10 fiscal years shown, annual revenue declined from $165.44M (FY 2016) to $55.23M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $68.67M |
| $76.75M |
| $77.42M |
| $92.33M |
| $122.84M |
| $104.68M |
| Operating income | -$140.10M | -$105.20M | -$263.68M | -$376.17M | -$446.10M | -$425.11M |
| Income tax | -$138.00K | -$239.00K | -$200.00K | $3.21M | $557.00K | $493.00K |
| Net income | -$164.00M | -$119.00M | -$276.00M | -$368.00M | -$524.00M | -$444.44M |
| EPS (diluted) | -$9.73 | -$8.68 | -$1.45 | -$1.97 | -$2.86 | -$2.49 |